Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Other ICR Research
  • View item
  • Home
  • ICR Divisions
  • Other ICR Research
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project.

Thumbnail
View/Open
Supporting information (63.31Kb)
Date
2017-02
ICR Author
Marsden,
Author
Applebaum, MA
Vaksman, Z
Lee, SM
Hungate, EA
Henderson, TO
London, WB
Pinto, N
Volchenboum, SL
Park, JR
Naranjo, A
Hero, B
Pearson, AD
Stranger, BE
Cohn, SL
Diskin, SJ
Show allShow less
Type
Journal Article
Metadata
Show full item record
Abstract
Background The incidence of second malignant neoplasm (SMN) within the first ten years of diagnosis in high-risk neuroblastoma patients treated with modern, intensive therapy is unknown. Further, the underlying germline genetics that contribute to SMN in these survivors are not known.Methods The International Neuroblastoma Risk Group (INRG) database of patients diagnosed from 1990 to 2010 was analysed. SMN risk was accessed by cumulative incidence, standardised incidence ratios (SIRs) and absolute excess risk. A candidate gene-based association study evaluated genetic susceptibility to SMN in neuroblastoma survivors.Results Of the 5987 patients in the INRG database with SMN data enrolled in a clinical trial, 43 (0.72%) developed a SMN. The 10-year cumulative incidence of SMN for high-risk patients was 1.8% (95% confidence interval [CI] 1.0-2.6%) compared with 0.38% (95% CI: 0.22-0.94%) for low-risk patients (P = 0.01). High-risk patients had an almost 18-fold higher incidence of SMN compared to age- and sex-matched controls (SIR = 17.5 (95% CI: 11.4-25.3), absolute excess risk = 27.6). For patients treated on high- and intermediate-risk clinical trials, the SIR of acute myelogenous leukaemia was 106.8 (95% CI: 28.7-273.4) and 127.7 (95%CI: 25.7-373.3), respectively. Variants implicating DNA repair genes XRCC3 (rs861539: P = 0.006; odds ratio: 2.04, 95%CI: 1.19-3.46) and MSH2 (rs17036651: P = 0.009; odds ratio: 0.26, 95% CI: 0.08-0.81) were associated with SMN.Conclusion The intensive multi-modality treatment strategy currently used to treat high-risk neuroblastoma is associated with a significantly increased risk of secondary acute myelogenous leukaemia. Defining the interactions of treatment exposures and genetic factors that promote the development of SMN is critical for optimising survivorship care.
URI
https://repository.icr.ac.uk/handle/internal/1397
DOI
https://doi.org/10.1016/j.ejca.2016.11.022
Collections
  • Other ICR Research
Subject
Humans
Neuroblastoma
Neoplasms, Second Primary
Genetic Predisposition to Disease
Combined Modality Therapy
Incidence
Risk Assessment
Risk Factors
DNA Repair
Adolescent
Adult
Child
Child, Preschool
Infant
Survivors
Female
Male
Leukemia, Myeloid, Acute
Young Adult
Genetic Association Studies
Language
eng
Date accepted
2016-11-15
License start date
2017-02
Citation
European journal of cancer (Oxford, England : 1990), 2017, 72 pp. 177 - 185

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.